Recruiter
ElegenSalary not specified
Full Time
Mid-level (3 to 4 years)
About Elegen
Elegen focuses on improving the process of manufacturing synthetic DNA to meet the needs of the bioeconomy. The company provides custom DNA synthesis services to researchers, biotech companies, and pharmaceutical firms that require high-quality and complex synthetic DNA for various applications, including biomanufacturing and mRNA-based treatments. Elegen uses advanced technologies to ensure fast turnaround times and high accuracy in DNA synthesis, which are essential for its clients' projects. Unlike its competitors, Elegen not only streamlines traditional DNA manufacturing workflows but also enables the production of valuable biologics and therapeutics. The company's goal is to support the development of next-generation mRNA medicines and other advanced therapeutics by providing reliable and efficient DNA solutions.
San Carlos, CaliforniaHeadquarters
2017Year Founded
$34MTotal Funding
SERIES_BCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Short Term Disability
Long Term Disability
Parental Leave
Commuter Benefits
Fitness Allowance
Learning Allowance
Risks
Increased competition from companies like Twist Bioscience in DNA synthesis capabilities.
Potential intellectual property disputes could impact Elegen's proprietary technologies.
Dependence on key partnerships, like GSK, could affect market position if dissolved.
Differentiation
Elegen's ENFINIA™ DNA offers rapid synthesis of highly complex DNA in 10 days.
The company provides cell-free DNA production, reducing contamination risks and improving efficiency.
Elegen's Early Access Program allows clients early access to high-complexity DNA breakthroughs.
Upsides
Elegen raised $35M to expand its ENFINIA™ DNA product line for clinical development.
Collaboration with GSK enhances Elegen's cell-free DNA technology for vaccines and medicines.
Elegen's ability to synthesize complex DNA sequences gives it a competitive market edge.
Funding
Total raised$34.05 M
Latest valuation$175.00 M
StageSERIES_B